{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:03:49Z","timestamp":1789646629660,"version":"4.0.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2022\/SKK06\/USM\/02\/13"],"award-info":[{"award-number":["FRGS\/1\/2022\/SKK06\/USM\/02\/13"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.intimp.2024.113597","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T18:46:43Z","timestamp":1732042003000},"page":"113597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Potential and limitations of IL-37, a cytokine targeted for therapy of systemic lupus erythematosus: A Systematic Review"],"prefix":"10.1016","volume":"144","author":[{"given":"Ummul Aqeela Balqees","family":"Mohamed Thaha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Majdiah","family":"Wan Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Rosmawati","family":"Nik Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norhayati","family":"Yusop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohimah","family":"Mohamud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Syamimee","family":"Wan Ghazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113597_b0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-med-043021-032611","article-title":"Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches","volume":"74","author":"Lazar","year":"2023","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.113597_b0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejim.2011.11.001","article-title":"Lupus: Novel therapies in clinical development","volume":"23","author":"Chugh","year":"2012","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.intimp.2024.113597_b0015","first-page":"3291","article-title":"Correlation between interleukin-10 and interleukin-12 levels with systemic lupus erythematosus and the effect of the age and gender, Eurasia","volume":"14","author":"Kadhum","year":"2020","journal-title":"J Biosci."},{"key":"10.1016\/j.intimp.2024.113597_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of SLE","volume":"16","author":"Pan","year":"2020","journal-title":"World J. Pediatr."},{"issue":"7","key":"10.1016\/j.intimp.2024.113597_b0025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.55563\/clinexprheumatol\/nolysy","article-title":"One Year in review 2022: Systemic lupus erythematosus","volume":"40","author":"Zucchi","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/cells9010072","article-title":"Anti-Cytokine Autoantibodies in Systemic Lupus Erythematosus","volume":"9","author":"Howe","year":"2020","journal-title":"Cells."},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.11613\/BM.2015.004","article-title":"Pathologic patterns of interleukin 10 expression - A review","volume":"25","author":"Trifunovi\u0107","year":"2015","journal-title":"Biochemia Medica."},{"key":"10.1016\/j.intimp.2024.113597_b0045","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.3390\/ijms232213829","article-title":"Multiplex Analysis of Serum Cytokine Profiles in Systemic Lupus Erythematosus and Multiple Sclerosis","volume":"23","author":"Melamud","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113597_b0050","doi-asserted-by":"crossref","unstructured":"M.A. Ameer, H. Chaudhry, J. Mushtaq, O.S. Khan, M. Babar, Hashim, et al., An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and Management, Cureus. 14 (10) (2022) 1\u201316, doi: 10.7759\/cureus.30330.","DOI":"10.7759\/cureus.30330"},{"key":"10.1016\/j.intimp.2024.113597_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02658","article-title":"Novel treatments in Lupus","volume":"9","author":"Vukelic","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113597_b0060","doi-asserted-by":"crossref","unstructured":"I. Rudloff,S.X. Cho, J.C. Lao, D. Ngo, M. McKenzie M, et al., Monocytes and Dendritic Cells Are the Primary Sources of Interleukin 37 in Human Immune Cells, J Leukoc Biol. 101 (4) (2017) 901\u201311.","DOI":"10.1189\/jlb.3MA0616-287R"},{"key":"10.1016\/j.intimp.2024.113597_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696605","article-title":"Current understanding of IL-37 in human health and disease","volume":"12","author":"Su","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0070","first-page":"7","article-title":"Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"S4","key":"10.1016\/j.intimp.2024.113597_b0075","first-page":"305","article-title":"Understanding Research Study Designs, Indian","volume":"23","author":"Ranganathan","year":"2019","journal-title":"Journal of Critical Care Medicine."},{"issue":"5","key":"10.1016\/j.intimp.2024.113597_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The strobe guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"10.1016\/j.intimp.2024.113597_b0085","doi-asserted-by":"crossref","unstructured":"P.A. Modesti, G. Reboldi, F. P. Cappuccio, C. Agyemang, G. Remuzzi, S. Rapi, E. Perruolo, G. Parati, Panethnic differences in blood pressure in Europe: A systematic review and meta-analysis, PLoS One. 11 (1) (2016):e0147601, doi: 10.1371\/journal.pone.0147601.","DOI":"10.1371\/journal.pone.0147601"},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0961203318815768","article-title":"Sexual dimorphism in SLE: Above and Beyond sex hormones","volume":"28","author":"Christou","year":"2018","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0961203309346505","article-title":"Sledai-2K for a 30-day window","volume":"19","author":"Touma","year":"2009","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.intimp.2024.113597_b0100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0961203319836717","article-title":"Performance of sledai-2K to detect a clinically meaningful change in SLE disease activity: A 36\u2013month prospective cohort study of 334 patients","volume":"28","author":"Jesus","year":"2019","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.intimp.2024.113597_b0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/08820139.2020.1869254","article-title":"Association between IL-37 and systemic lupus erythematosus risk","volume":"51","author":"Wu","year":"2021","journal-title":"Immunol. Invest."},{"issue":"12","key":"10.1016\/j.intimp.2024.113597_b0110","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/1744666X.2022.2108792","article-title":"Rationale for IL-37 as a novel therapeutic agent in inflammation","volume":"18","author":"Nold-Petry","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113597_b0115","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.berh.2005.05.006","article-title":"New treatments for SLE: Cell-depleting and anti-cytokine therapies","volume":"19","author":"Anolik","year":"2005","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"15","key":"10.1016\/j.intimp.2024.113597_b0120","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.3390\/ijms22158076","article-title":"Mast cell cytokines IL-1, IL-33, and IL-36 mediate skin inflammation in psoriasis: A novel therapeutic approach with the anti-inflammatory cytokines IL-37, IL-38, and IL-1Ra","volume":"22","author":"Conti","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.intimp.2024.113597_b0125","doi-asserted-by":"crossref","first-page":"14883","DOI":"10.3390\/ijms241914883","article-title":"Characterization of serum cytokine profiles of patients with active lupus nephritis","volume":"24","author":"Rahm\u00e9","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2024.113597_b0130","first-page":"11201","article-title":"Discoid lupus erythematosus: A cross-sectional study from the Sindh Institute of Skin Diseases, Karachi, Pakistan","volume":"12","author":"Ashraf","year":"2020","journal-title":"Cureus."},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1681\/ASN.2019050545","article-title":"Additive therapeutic effects of mesenchymal stem cells and IL-37 for systemic lupus erythematosus","volume":"31","author":"Xu","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113597_b0140","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1189\/jlb.3MA0616-287R","article-title":"Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells","volume":"101","author":"Rudloff","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113597_b0145","first-page":"1269","article-title":"AB0161 interleukin-37: A therapeutic for lupus nephritis in MRL-FASLPR MICE, SLE, Sj\u00f6gren\u2019s and APS \u2013 Etiology","volume":"77","author":"Ding","year":"2018","journal-title":"Pathogenesis and Animal Models."},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10875-012-9791-z","article-title":"Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus","volume":"33","author":"Song","year":"2012","journal-title":"J. Clin. Immunol."},{"issue":"69","key":"10.1016\/j.intimp.2024.113597_b0155","article-title":"IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity","volume":"12","author":"Ye","year":"2014","journal-title":"J Transl Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0160","doi-asserted-by":"crossref","first-page":"34604","DOI":"10.1038\/srep34604","article-title":"Clinical Associations of IL-10 and IL-37 in systemic lupus erythematosus","volume":"6","author":"Godsell","year":"2016","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2024.113597_b0165","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/0961203316646462","article-title":"Elevated plasma interleukin-37 levels in systemic lupus erythematosus patients","volume":"25","author":"Wu","year":"2016","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.intimp.2024.113597_bib285","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/08820139.2020.1869254","article-title":"Association between IL-37 and systemic lupus erythematosus risk","volume":"51","author":"Wu","year":"2021","journal-title":"Immunological Investigations"},{"issue":"4","key":"10.1016\/j.intimp.2024.113597_b0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.reumae.2023.03.004","article-title":"Relative CTLA-4, PTPN-22, and interleukin 37 mRNA expressions in patients with lupus nephritis","volume":"19","author":"Moneim","year":"2023","journal-title":"Reumatolog\u00eda Cl\u00ednica (english Edition)."},{"key":"10.1016\/j.intimp.2024.113597_b0175","doi-asserted-by":"crossref","unstructured":"S.I. Nasef, H.H. Omar, A. Ellawindy, H.H. Omar, A.A. Hashem, N.M. Abd El-Fadeal, M.G. Tawfik, Double risk of interleukin-37 RS3811047 a allele polymorphism with lupus nephritis in an Egyptian population, The Egyptian Rheumatologist. 45 (4) (2023) 303\u2013308, doi: 10.1016\/j.ejr.2023.08.005.","DOI":"10.1016\/j.ejr.2023.08.005"},{"key":"10.1016\/j.intimp.2024.113597_b0180","doi-asserted-by":"crossref","unstructured":"R.A. Nijeeb, A.A. Aljber, A.H. Ad\u2019hiah, Exon 2 variants (RS3811046 and RS3811047) of the IL-37 gene are associated with susceptibility to systemic lupus erythematosus, Egyptian Journal of Basic and Applied Sciences. 11 (1) (2024) 269\u2013280, doi: 10.1080\/2314808x.2024.2336702.","DOI":"10.1080\/2314808X.2024.2336702"},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0185","first-page":"e11377","article-title":"Level of interleukin 37 (IL-37) in children with systemic lupus erythematosus and its correlation with disease activity","volume":"28","author":"Ghobrial","year":"2018","journal-title":"Iran. J. Pediatr."},{"issue":"19","key":"10.1016\/j.intimp.2024.113597_b0190","doi-asserted-by":"crossref","first-page":"14883","DOI":"10.3390\/ijms241914883","article-title":"Characterization of serum cytokine profiles of patients with active lupus nephritis","volume":"24","author":"Rahm\u00e9","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2024.113597_b0195","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/1756-185X.13122","article-title":"Serum interleukin-37: A new player in lupus nephritis?","volume":"20","author":"Tawfik","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113597_b0200","doi-asserted-by":"crossref","unstructured":"Xu. Teng, Z. Hu, X. Wei, et al., IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production, The Journal of Immunology. 192 (4) (2014) 1815\u20131823, doi: 10.4049\/jimmunol.1300047.","DOI":"10.4049\/jimmunol.1300047"},{"issue":"4","key":"10.1016\/j.intimp.2024.113597_b0205","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/all.12566","article-title":"IL-37 requires IL-18R\u03b1 and SIGIRR\/Il-1R8 to diminish allergic airway inflammation in mice","volume":"70","author":"Lunding","year":"2015","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.intimp.2024.113597_b0210","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/rheumatology\/kew325","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation","volume":"55","author":"Cavalli","year":"2016","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.intimp.2024.113597_b0215","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1159\/000487344","article-title":"Transgenic overexpression of IL-37 protects against atherosclerosis and strengthens plaque stability","volume":"45","author":"Liu","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"4","key":"10.1016\/j.intimp.2024.113597_b0220","first-page":"1019","article-title":"Mesenchymal stem cells and IL-37: a powerful combination","volume":"33","author":"Gugliandolo","year":"2019","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"2","key":"10.1016\/j.intimp.2024.113597_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/acel.13309","article-title":"Interleukin-37 improves t-cell-mediated immunity and chimeric antigen receptor t-cell therapy in aged backgrounds","volume":"20","author":"Hamilton","year":"2021","journal-title":"Aging Cell"},{"issue":"5","key":"10.1016\/j.intimp.2024.113597_b0230","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/1708538120921735","article-title":"The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis","volume":"28","author":"Lotfy","year":"2020","journal-title":"Vascular"},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.47435","article-title":"IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5\/Il-1R8","volume":"11","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2021","journal-title":"Theranostics."},{"key":"10.1016\/j.intimp.2024.113597_b0240","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.1944","article-title":"IL-37 is a fundamental inhibitor of innate immunity","volume":"11","author":"Nold","year":"2010","journal-title":"Nat Immunol."},{"issue":"40","key":"10.1016\/j.intimp.2024.113597_b0245","doi-asserted-by":"crossref","first-page":"16711","DOI":"10.1073\/pnas.1111982108","article-title":"Interleukin 37 expression protects mice from colitis","volume":"108","author":"McNamee","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2024.113597_b0250","doi-asserted-by":"crossref","first-page":"e1004462","DOI":"10.1371\/journal.ppat.1004462","article-title":"IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis","volume":"10","author":"Moretti","year":"2014","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.intimp.2024.113597_b0255","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/aps.2015.51","article-title":"IL-37B gene transfer enhances the therapeutic efficacy of mesenchumal stromal cells in DSS-induced colitis mice","volume":"36","author":"Wang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.intimp.2024.113597_b0260","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/eji.201545828","article-title":"Suppression of innate inflammation and immunity by Interleukin-37","volume":"46","author":"Dinarello","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2024.113597_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1278521","article-title":"Novel insights into IL-37: An anti-inflammatory cytokine with emerging roles in anti-cancer process","volume":"14","author":"Gu","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113597_b0270","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/cells9010178","article-title":"Parsing the IL-37-mediated suppression of inflammasome function","volume":"9","author":"Rudloff","year":"2020","journal-title":"Cells."},{"issue":"2","key":"10.1016\/j.intimp.2024.113597_b0275","article-title":"Approved biologics for SLE: which to try first and in which patients? - The case for anifrolumab, Lupus","volume":"10","author":"Morand","year":"2023","journal-title":"Science & Medicine."},{"key":"10.1016\/j.intimp.2024.113597_b0280","article-title":"Strategies of Targeting Inflammasome in the Treatment of Systemic Lupus Erythematosus","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924021192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924021192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:34:50Z","timestamp":1789644890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924021192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":57,"alternative-id":["S1567576924021192"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113597","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential and limitations of IL-37, a cytokine targeted for therapy of systemic lupus erythematosus: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113597","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113597"}}